- Home
- BMRA vs VYNE Comparison
BMRA vs VYNE Comparison
Compare BMRA & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMRA
- VYNE
- Stock Information
- Founded
- BMRA 1971
- VYNE 2003
- Country
- BMRA United States
- VYNE United States
- Employees
- BMRA N/A
- VYNE N/A
- Industry
- BMRA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- BMRA Health Care
- VYNE Health Care
- Exchange
- BMRA Nasdaq
- VYNE Nasdaq
- Market Cap
- BMRA 8.2M
- VYNE 7.9M
- IPO Year
- BMRA N/A
- VYNE 2018
- Fundamental
- Price
- BMRA N/A
- VYNE $0.43
- Analyst Decision
- BMRA
- VYNE Buy
- Analyst Count
- BMRA 0
- VYNE 2
- Target Price
- BMRA N/A
- VYNE $8.00
- AVG Volume (30 Days)
- BMRA 33.1K
- VYNE 3.1M
- Earning Date
- BMRA 10-10-2025
- VYNE 11-06-2025
- Dividend Yield
- BMRA N/A
- VYNE N/A
- EPS Growth
- BMRA N/A
- VYNE N/A
- EPS
- BMRA N/A
- VYNE N/A
- Revenue
- BMRA $5,311,000.00
- VYNE $476,000.00
- Revenue This Year
- BMRA N/A
- VYNE N/A
- Revenue Next Year
- BMRA N/A
- VYNE N/A
- P/E Ratio
- BMRA N/A
- VYNE N/A
- Revenue Growth
- BMRA N/A
- VYNE N/A
- 52 Week Low
- BMRA $2.08
- VYNE $0.28
- 52 Week High
- BMRA $10.16
- VYNE $4.30
- Technical
- Relative Strength Index (RSI)
- BMRA 45.61
- VYNE 60.37
- Support Level
- BMRA $2.68
- VYNE $0.32
- Resistance Level
- BMRA $2.83
- VYNE $0.35
- Average True Range (ATR)
- BMRA 0.11
- VYNE 0.02
- MACD
- BMRA 0.01
- VYNE 0.02
- Stochastic Oscillator
- BMRA 54.84
- VYNE 84.88
About BMRA Biomerica Inc.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.